Literatür Detay Bilgisi
Idelalisib, Ibrutinib Show Benefits in CLL.
Yazarlar : [No authors listed]
Yayın : Cancer Discov.
Yayın Yılı : 2014
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/24706642
Konu : Lenfoma
Literatür İçeriği : Separate trials report strikingly positive results for idelalisib and ibrutinib in the treatment of patients with chronic lymphocytic leukemia, leading some researchers to suggest that patients could rely on targeted therapies and forego chemotherapy.
Konusu Aynı Olan Diğer Materyaller
Sunumlar | Videolar | Olgu Tartışması |